News
This is The Takeaway from today's Morning Brief, which you can sign up to receive in your inbox every morning along with: The chart of the day What we're watching What we're reading Economic data ...
Stock award propelled Rick Smith past Apple’s Tim Cook and Blackstone’s Schwarzman to the top of WSJ’s annual ranking. Continue Reading View Comments ...
The government’s monthslong quest to wring savings from federal contractors is widening and entering a new phase. The Trump administration is moving its spending review beyond consulting firms such as ...
$OPGN ($OPGN) is expected to release its quarterly earnings data on Monday, June 2nd after market close, per Finnhub. Analysts are expecting revenue of $612,000 and earnings of -$0.06 per share. You c ...
Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...
White House says next space agency leader should be completely aligned with ‘President Trump’s America First agenda.’ Continue Reading View Comments ...
(Bloomberg) -- The White House said on Saturday it would name a new nominee for NASA administrator, just days before billionaire Jared Isaacman, the current pick, was to face his planned Senate confir ...
[Pancreatitis, pancreatic cancer, Asian doctor with pancreas, gallbladder and bile duct human anatomy model at hospital.] sasirin pamai/iStock via Getty Images Actuate Therapeutics (NASDAQ:ACTU [https ...
[Solar panels are installed on the roof] lamsaang/iStock via Getty Images Swiss solar panel manufacturer Meyer Burger Technology (OTCPK:MYBUF [https://seekingalpha.com/symbol/MYBUF]) on Saturday said ...
Merck's KEYTRUDA Combo Cuts Risk By 35% In First-Line PD-L1+ Metastatic TNBC, Phase 3 Study Confirms
(RTTNews) - Merck & Co Inc. (MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus c ...
(RTTNews) - Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrog ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results